Resistance mutations are rare among protease inhibitor treatment-naive hepatitis C genotype-1 patients with or without HIV coinfection.

@article{LisboaNeto2015ResistanceMA,
  title={Resistance mutations are rare among protease inhibitor treatment-naive hepatitis C genotype-1 patients with or without HIV coinfection.},
  author={G. Lisboa-Neto and C. F. Noble and J. Pinho and F. Malta and M. Gomes‐Gouv{\^e}a and M{\'o}nica V. Alvarado-Mora and M. H. da Silva and A. G. Leite and Leonora Z Piccoli and F. Rodrigues and F. Carrilho and M. Mendes-Corr{\^e}a},
  journal={Antiviral therapy},
  year={2015},
  volume={20 3},
  pages={
          281-7
        }
}
BACKGROUND HCV has a high replication rate and a lack of proofreading activity, leading to a greatly diverse viral population. This diversity may lead to emergence of resistant strains in direct-acting antiviral therapy. The frequency of naturally occurring HCV protease inhibitor (PI) mutations has been addressed in many countries, but there are few data on the prevalence of these mutations in Brazilian patients. METHODS We evaluated the sequence of HCV NS3 protease gene in 247 patients (135… Expand
17 Citations
Resistance-associated mutations to HCV protease inhibitors naturally pre-existed in HIV/HCV coinfected, treatment-naïve patients.
  • 3
Resistance-associated variants in HCV subtypes 1a and 1b detected by Ion Torrent sequencing platform.
  • 11
...
1
2
...

References

SHOWING 1-10 OF 40 REFERENCES
The role of resistance in HCV treatment.
  • 117
...
1
2
3
4
...